Form 4 Lantheus Holdings Inc: Mary Anne Heino (Director, Executive Chair and CEO) For: 17 November
This article reports on a Form 4 filing for Lantheus Holdings Inc, detailing insider transactions by Mary Anne Heino, who serves as a Director, Executive Chair, and CEO. The filing pertains to activity on November 17. The article briefly mentions the company's stock symbol, LNTH, and its current performance.
PharmaLogic buys Lantheus' New Jersey radiopharma plant with a supply deal attached
PharmaLogic is acquiring Lantheus' contract manufacturing unit and its radiopharmaceutical plant in Springfield, New Jersey. This deal includes a long-term supply agreement for PharmaLogic's Agilera unit to manufacture lutetium Lu 177 dotatate for Lantheus. The acquisition positions Agilera to expand its radioligand therapy CDMO services, adding a crucial US-based theranostic manufacturing site to its existing European operations.
A fund adviser reports 3.9 million Lantheus (LNTH) shares with shared voting power.
Pentwater Capital Management LP and Matthew Halbower have reported a 6.0% passive stake in Lantheus Holdings, Inc. (LNTH), amounting to 3,900,000 shares. These shares are held directly by Pentwater Funds, with both reporting persons exercising shared voting and dispositive power. This disclosure is based on Lantheus having 65,299,875 shares outstanding as of September 1, 2026.
One asset manager reports shared voting power over 2.77 million Lantheus (LNTH) shares.
Janus Henderson Group Ltd. has filed an amended Schedule 13G, disclosing beneficial ownership of 2,770,384 shares, representing a 4.2% stake in Lantheus Holdings, Inc. (LNTH). The asset manager reported shared voting and dispositive power over these shares, indicating that investment and voting discretion is exercised for client portfolios, with the Managed Portfolios receiving dividends and sale proceeds. None of the individual Managed Portfolios own more than 5% of LNTH common stock.
Lantheus reports Phase 3 trial results for Alzheimer’s tau imaging agent
Lantheus Holdings Inc. announced positive results from two pivotal Phase 3 studies for its investigational PET imaging agent, TAUKLARIFY (florquinitau F 18 injection), designed to identify neurofibrillary tangle pathology in adults being evaluated for Alzheimer’s disease. The studies met their co-primary endpoints of sensitivity and specificity across independent readers and showed the tracer was generally well tolerated with few reported adverse events. These findings were presented at the Clinical Trials on Alzheimer’s Disease meeting in Boston.
Lantheus Reports Positive Phase 3 Results for TAUKLARIFY PET Imaging in Alzheimer’s Disease Assessment
Lantheus Holdings, Inc. announced positive Phase 3 results for its TAUKLARIFY™ (florquinitau F 18 injection) PET imaging agent, supporting its use in diagnosing tau neurofibrillary tangles in adults being evaluated for Alzheimer’s disease. The studies, presented at CTAD 2026, demonstrated high sensitivity and specificity, with all independent readers meeting primary endpoints, indicating reliable diagnostic performance. TAUKLARIFY™ is designed to provide complementary insights alongside amyloid beta imaging to better characterize Alzheimer's disease.
Eight partnerships hold the shares behind Farallon's reported Lantheus (LNTH) stake.
Farallon Capital Management, L.L.C. has reported a 4.8% ownership stake in Lantheus Holdings, Inc. (LNTH), amounting to 3,111,254 shares as of September 30, 2026. These shares are held across eight Farallon investment partnerships, with various managing and senior managing members sharing voting and dispositive power. The filing, an amendment to a passive investment disclosure, details the beneficial ownership and the identities of the reporting persons.
PharmaLogic Buys Lantheus' Springfield Site to Build First Transatlantic Radiopharmaceutical CDMO
PharmaLogic Holdings has acquired Lantheus Holdings' CDMO business and Springfield, New Jersey manufacturing facility, marking a significant step towards creating the first transatlantic radiopharmaceutical contract development and manufacturing organization (CDMO). This acquisition expands PharmaLogic's U.S. therapeutic radiopharmaceutical capacity, complementing its existing European operations and enabling a unified platform for radioligand therapies from clinical development to global supply. The deal also includes a long-term supply agreement for lutetium Lu 177 dotatate, securing a key customer and ensuring continued supply for Lantheus' recently approved radiotherapeutic.
PharmaLogic to acquire Lantheus' radiopharma manufacturing business in New Jersey
PharmaLogic Holdings Corp. is set to acquire Lantheus Holdings' radiopharma contract development and manufacturing organization (CDMO) business and manufacturing facility in Springfield, New Jersey. This acquisition will expand PharmaLogic's U.S. radiopharmaceutical production capacity, with the facility and its employees becoming part of PharmaLogic's therapeutic CDMO business, Agilera. The agreement also includes a long-term supply arrangement for the manufacture of lutetium Lu 177 dotatate for Lantheus.
A 3M-share sale takes Lantheus below 5% ownership of Perspective Therapeutics (CATX).
Lantheus Alpha Therapy, LLC, a subsidiary of Lantheus Holdings, Inc., reported open-market sales of 1,000,000 shares of Perspective Therapeutics (CATX) on October 5, 2026, and 3,000,000 shares on November 10, 2026. These sales reduced Lantheus's beneficial ownership in CATX to 3.9% from 120,758,815 shares outstanding, falling below the 5% threshold and marking their final exit filing.
PharmaLogic to Acquire Lantheus' CDMO Unit and Springfield Manufacturing Site, Enhancing Radiopharmaceutical Capabilities
PharmaLogic Holdings Corp. is set to acquire Lantheus Holdings, Inc.'s contract development and manufacturing organization (CDMO) business and its Springfield, New Jersey manufacturing facility. This strategic acquisition will expand PharmaLogic's U.S. manufacturing capabilities for radioligand therapies and establish it as the first therapeutic CDMO with a transatlantic platform for such production. The deal also includes a long-term supply agreement where PharmaLogic's division, Agilera, will produce lutetium Lu 177 dotatate for Lantheus.
PharmaLogic Acquires Lantheus CDMO Unit, Expands U.S. Radiopharma Capacity
PharmaLogic Holdings Corp. has acquired the CDMO business and radiopharmaceutical manufacturing facility in Springfield, NJ from Lantheus Holdings Inc. This deal expands PharmaLogic's U.S. radiopharmaceutical production capabilities and establishes the first transatlantic CDMO platform dedicated to radioligand therapies. The acquisition includes a long-term supply agreement for Agilera, PharmaLogic's therapeutic CDMO business, to manufacture lutetium Lu 177 dotatate for Lantheus.
A New Jersey manufacturing plant is part of Lantheus (LNTH)'s planned business sale.
Lantheus Holdings, Inc. (LNTH) has agreed to sell its contract development and manufacturing organization (CDMO) business and its Springfield, New Jersey manufacturing facility to PharmaLogic Holdings Corp. The agreement, signed on November 8, 2026, also includes a long-term supply agreement where PharmaLogic's Agilera franchise will manufacture lutetium Lu 177 dotatate for Lantheus. This transaction is subject to customary closing conditions.
PharmaLogic to acquire Lantheus CDMO business and manufacturing facility
PharmaLogic Holdings Corp. has agreed to acquire Lantheus Holdings, Inc.'s contract development and manufacturing organisation (CDMO) business and its Springfield, New Jersey manufacturing facility. This acquisition will expand PharmaLogic’s US capacity for radiopharmaceutical therapeutics and establish a transatlantic platform for radioligand therapies, supporting them from early clinical development through commercial launch. The agreement also includes a long-term supply arrangement where Agilera, PharmaLogic's therapeutic CDMO business, will manufacture lutetium Lu 177 dotatate for Lantheus.
PharmaLogic to acquire Lantheus CDMO business and New Jersey radiopharma plant
PharmaLogic, a radiopharmaceutical CDMO, has signed an agreement to acquire the CDMO business and Springfield, New Jersey manufacturing facility from Lantheus. This acquisition will make PharmaLogic the first therapeutic CDMO with a transatlantic platform for radioligand therapies, covering development, commercial launch, and global supply. The deal also includes a long-term supply agreement where PharmaLogic's Agilera franchise will manufacture lutetium Lu 177 dotatate for Lantheus.
PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility
PharmaLogic Holdings Corp. announced a definitive agreement to acquire Lantheus Holdings, Inc.'s CDMO business and its Springfield, New Jersey manufacturing facility. This acquisition expands PharmaLogic's U.S. therapeutic manufacturing capacity and establishes the first transatlantic CDMO platform specializing in radioligand therapies. The deal also includes a long-term supply agreement for Agilera, PharmaLogic's therapeutic CDMO franchise, to manufacture lutetium Lu 177 dotatate for Lantheus.
Lantheus Holdings Inc earnings beat by $0.42, revenue topped estimates
Lantheus Holdings Inc (NASDAQ: LNTH) reported strong third-quarter results, beating analyst estimates with an EPS of $1.68 against a projected $1.26. The company also exceeded revenue expectations, bringing in $389.9 million compared to the consensus estimate of $360.82 million. The stock has shown significant growth, rising 88.38% in the last 12 months.
No voting power accompanies Abigail P. Johnson’s reported stake in Lantheus (LNTH).
FMR LLC and Abigail P. Johnson have reported beneficial ownership of 111,461.42 shares, or 0.2%, of Lantheus Holdings, Inc. (LNTH) common stock as of September 30, 2026. While FMR LLC holds sole voting power over 88,841.15 shares, Abigail P. Johnson is listed with zero sole voting power, indicating she does not have direct control over voting decisions despite her beneficial ownership. Both parties, however, share sole dispositive power over the entire 111,461.42 shares.
Lantheus Holdings Inc earnings beat by $0.42, revenue topped estimates
Lantheus Holdings Inc (NASDAQ: LNTH) announced strong third-quarter results, beating analyst EPS estimates by $0.42 with earnings of $1.68 per share and surpassing revenue expectations with $389.9 million. The company's stock has shown significant growth, increasing 0.19% in the last three months and 88.38% over the past year. InvestingPro rates Lantheus Holdings Inc's financial health as "great performance."
Form 10-Q Lantheus Holdings, Inc. For: Sep 30
This article announces the filing of a Form 10-Q by Lantheus Holdings, Inc. for the period ending September 30. It provides a link to the SEC filing and notes that the document was filed on November 5, 2026.
Form 8K Lantheus Holdings Inc For: 5 November By Investing.com
This article reports on the filing of a Form 8K by Lantheus Holdings Inc. on November 5. The content is concise, primarily serving as a notification of the filing and referencing Lantheus Holdings Inc. (LNTH).
Lantheus Welcomes CMS CY27 Final Rule Advancing Access to Diagnostic Radiopharmaceuticals
Lantheus Holdings, Inc. announced its approval of the CMS Calendar Year 2027 final rule, which maintains separate payment for diagnostic radiopharmaceuticals and extends Transitional Pass-Through status for PYLARIFY TruVu™ through September 30, 2029. This decision, along with the assignment of a permanent HCPCS code A9613 for PYLARIFY TruVu, aims to improve patient access to advanced diagnostic imaging for prostate cancer and provides reimbursement certainty for hospitals. Lantheus emphasizes the importance of these policies in supporting innovative radiopharmaceutical technologies and informed treatment decisions.
Lantheus Reports Third Quarter 2026 Financial Results
Lantheus Holdings, Inc. reported third-quarter 2026 financial results, with worldwide revenue increasing 1.5% to $389.9 million. The company announced FDA approvals for TAUKLARIFY™ and BRAVNETSA™, and detailed its definitive agreement to merge with Curium in an all-cash transaction valued at up to approximately $8.0 billion. Due to the pending merger, Lantheus has suspended its full-year 2026 financial guidance.
Lantheus Holdings, Inc. (LNTH) Seasonal Returns Chart
The article provides a snapshot of Lantheus Holdings, Inc. (LNTH) stock information, including its real-time price, daily change, and overnight trading activity. It notes that seasonality data is currently unavailable for LNTH. The page seems to be a financial data page from Yahoo Finance for the company.
Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting
Lantheus Holdings, Inc. announced that data will be featured at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting. The presentations will cover the diagnostic performance of florquinitau F 18 PET in detecting tau pathology in early Alzheimer’s disease and the minimal age dependence of astrocytic MAO-B with 18F-FDED PET imaging. These findings highlight Lantheus's commitment to advancing radiopharmaceutical solutions for disease detection and patient outcomes.
Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer’s Disease Annual Meeting
Lantheus Holdings, Inc. will present data at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting in Boston, MA. The presentations will cover the diagnostic performance of florquinitau F 18 PET in detecting tau pathology in early Alzheimer’s disease and the minimal age dependence of astrocytic MAO-B with 18F-FDED PET Imaging across the Alzheimer's disease spectrum. These findings highlight Lantheus's contributions to radiopharmaceutical solutions for disease diagnosis.
Avoiding Lag: Real-Time Signals in (LNTH) Movement
This article provides an AI-generated analysis of Lantheus Holdings Inc. (NASDAQ: LNTH), indicating a neutral near- and mid-term outlook with a positive long-term bias, but elevated downside risk. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths and support/resistance levels for various time horizons.
Lantheus Holdings, Inc. (1LNTH.MI) Seasonal Returns Chart
The article presents a seasonal returns chart for Lantheus Holdings, Inc. (1LNTH.MI), displaying the average monthly price return from 2025-2026, with options to view data over 3, 5, 10, 20 years, or all available data. As of September 30, the stock was trading at 88.70 EUR, up 0.11%.
Vanguard amends its Lantheus (LNTH) stake report, with sole voting power over 60,159 shares.
Vanguard Portfolio Management LLC has filed an amended Schedule 13G/A, reporting a 4.88% passive stake in Lantheus Holdings, Inc. (LNTH) as of September 30, 2026. The report indicates Vanguard has sole dispositive power over 3,189,870 shares and sole voting power over 60,159 shares. This filing provides updated ownership details for Vanguard's holdings in Lantheus.
Lantheus Holdings stock heads into results with merger review pending
Lantheus Holdings stock is under investor scrutiny as the company approaches its third-quarter results amidst an extended FTC review of its proposed merger with Curium. Analysts are closely watching the performance of PYLARIFY, Lantheus's prostate cancer imaging agent, which saw a decline in Q2 sales, while the FTC's second request for information adds uncertainty to the merger timeline. The company had previously suspended its full-year guidance due to the pending transaction, making management commentary on commercial execution and regulatory updates crucial for investors.
Lantheus Holdings, Inc. Estimates – NASDAQ:LNTH
This article provides an overview of Lantheus Holdings, Inc. (NASDAQ: LNTH) financial estimates and actuals through TradingView. It allows users to explore reported financial data and analyst estimates across various statements and metrics, comparing actual results with average, high, and low estimates. The platform also enables visualization of trends over time for income statements, balance sheets, and cash flow.
Lantheus Holdings Inc Estimates – FWB:0L8
This page on TradingView provides financial estimates and actuals for Lantheus Holdings Inc (FWB:0L8) listed on the Frankfurt Stock Exchange. It offers a comprehensive view of the company's financial data across income statements, balance sheets, cash flow statements, and valuation metrics, allowing users to compare reported results with analyst estimates. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Lantheus Holdings Inc Estimates – GETTEX:0L8
This article provides an overview of the financial estimates for Lantheus Holdings Inc (0L8) on Gettex via TradingView. It highlights sections for exploring reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, allowing users to compare actual results with average, high, and low estimates. The content focuses on fundamental and statistical data for the company.
FTC Second Requests Extend HSR Waiting Period for Curium-Lantheus Deal
The Federal Trade Commission (FTC) has issued Second Requests to Curium US Holdings LLC and Lantheus Holdings, extending the Hart-Scott-Rodino waiting period for Curium's proposed acquisition of Lantheus. The companies expect to respond promptly and still aim for a first-half 2027 closing for the approximately $8 billion deal, which includes a potential contingent value right for Lantheus shareholders.
Form 8K Lantheus Holdings Inc For: 22 October By Investing.com
Lantheus Holdings Inc. (LNTH) filed a Form 8K on October 22, 2026. The article from Investing.com provides no further details about the content of the Form 8K filing itself but notes the date and the company involved.
Mizuho target puts Lantheus Holdings stock 8.58 percent below USD 109.00
Mizuho has reaffirmed a Neutral rating for Lantheus Holdings but lowered its price target from USD 115.00 to USD 109.00. This revised target is 8.58 percent above the Nasdaq price of USD 100.39 as of October 20, 2026. The company reported USD 388.18 million in second-quarter revenue and has a market capitalization of USD 6.6 billion.
Lobbying Update: $290,900 of LANTHEUS HOLDINGS INC. lobbying was just disclosed
LANTHEUS HOLDINGS INC. (LNTH) recently disclosed $290,900 in lobbying expenditures for Q3 2026. The article also details significant hedge fund activity, with 224 institutional investors increasing their positions and 175 decreasing them, and lists recent price targets from four analysts, with a median target of $115.0.
Lobbying Update: $290,900 of LANTHEUS HOLDINGS INC. lobbying was just disclosed
Lantheus Holdings Inc. (LNTH) recently disclosed $290,900 in lobbying expenditures for Q3 2026, as per a new Lobbying Disclosure Act filing. The article also details significant institutional investor activity in LNTH stock, with several firms adding or removing shares in recent quarters. Furthermore, it provides recent analyst price targets for LNTH, with a median target of $115.0 from four analysts.
Mizuho cuts Lantheus target from USD 115.00 to USD 109.00 for Lantheus Holdings stock
Mizuho has lowered its price target for Lantheus Holdings (LNTH) stock from $115.00 to $109.00, while reaffirming a Neutral rating. This adjustment comes ahead of the company's anticipated third-quarter earnings report on November 5, 2026. Lantheus reported strong second-quarter revenues of $388.18 million, exceeding analyst estimates, but its stock closed at $99.70 on October 16, 2026, down slightly from the previous close.
Lantheus Holdings (LNTH) Could Be 7% Undervalued As Its Pipeline Story Builds
Lantheus Holdings (LNTH) is considered modestly undervalued, trading near $99.99 with a narrative fair value of approximately $107.74. The company's pipeline, including new radiodiagnostics and radiotherapeutics like BRAVNETSA, OCTEVY, LNTH-2513 GP1, and LNTH-2401, is expected to drive future revenue and margin growth. However, potential risks such as PSMA PET pricing pressure or regulatory setbacks could impact its performance.
Lantheus Holdings (LNTH) Could Be 7% Undervalued As Its Pipeline Story Builds
Lantheus Holdings (LNTH) is considered modestly undervalued, with a fair value estimated at $107.74 against its current price of $99.99, despite recent short-term share price softening. The company's pipeline of new radiodiagnostics and radiotherapeutics, including BRAVNETSA and late-stage assets, suggests potential for future revenue and margin growth. However, risks such as PSMA PET pricing pressure or regulatory delays could impact its trajectory.
Update: Market Chatter: JPMorgan Leads, Jefferies Joins $4.25 Billion Financing for Lantheus Deal
JPMorgan Chase is reportedly leading a $4.25 billion financing deal for Lantheus, with Jefferies joining as a participant. The article from MT Newswires provides an update on this market chatter, though full details are behind a premium paywall.
Banks Vie to Back $4.25B Debt for Curium-Lantheus
Lenders are competing for roles in a $4.25 billion financing package to support Curium's acquisition of Lantheus Holdings Inc., with JPMorgan leading the effort. The debt includes a large term loan, a revolving credit line, and a pre-arranged $1.125 billion payment-in-kind facility. This financing is expected to be syndicated to investors next year and will be a key indicator of market appetite for new leveraged loans.
Lantheus Holdings (NasdaqGM:LNTH) Stock Forecast & Analyst Predictions
Lantheus Holdings (LNTH) is forecast to grow earnings by 26% and revenue by 9.1% per annum. The company is facing a pending acquisition by Curium US LLC for up to $8 billion, which is shifting analyst focus from fundamentals to deal mechanics and contingent value rights. Recent FDA approvals for PYLARIFY TruVu and TAUKLARIFY, along with progress in new clinical trials, are contributing to the company's growth outlook despite some near-term uncertainties and past competitive pressures.
LNTH Downgraded by Mizuho -- Price Target Lowered to $109
Mizuho downgraded Lantheus Holdings (LNTH) to a Neutral rating, lowering its price target from $115.00 to $109.00, reflecting cautious sentiment from analysts. While LNTH has a strong GF Score™ of 82/100, indicating solid fundamentals, it is currently assessed as 11.9% overvalued by GuruFocus, with a market price of $100.11 against a GF Value™ of $89.47. Investors are advised to approach the stock with caution due to its overvaluation and lack of strong momentum.
Technical Reactions to LNTH Trends in Macro Strategies
This article provides a technical analysis of Lantheus Holdings Inc. (NASDAQ: LNTH) by the Quantitative Research Desk. It indicates a neutral near and mid-term outlook but a positive long-term bias, noting elevated downside risk due to a lack of additional long-term support signals. The analysis includes AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis with support and resistance levels.
Lantheus Holdings, Inc. (LNTH) Stock Forecasts
Argus has raised its target price for Lantheus Holdings Inc. (LNTH) to $105.00, with the company's current stock price at $100.33. Lantheus Holdings develops diagnostic products for the U.S. healthcare sector. The report, dated October 7, 2026, also mentions other related reports with target price adjustments for various companies.
Lantheus Holdings (LNTH) Gains CMS Reimbursement Win Following A Fair Value Debate
Lantheus Holdings (LNTH) recently secured a significant reimbursement victory with CMS granting Transitional Pass Through payment status and a permanent HCPCS code for its PYLARIFY TruVu PET imaging agent. Despite a recent cool-down in short-term momentum, the company's share price has seen substantial year-to-date and one-year gains, trading near its fair value of $107.74. This reimbursement win adds to the company's positive trajectory, particularly as it approaches an acquisition by Curium for $102.50 per share cash plus potential CVRs.
Lantheus Holdings stock gets CMS status for PYLARIFY TruVu
Lantheus Holdings (LNTH) has secured transitional pass-through status from CMS for its PYLARIFY TruVu product, effective October 1, 2026. This designation allows for separate reimbursement in hospital outpatient settings, supporting the product's launch and improving manufacturing efficiency. Despite strong second-quarter revenue of $388.18 million, beating consensus estimates, analysts currently maintain a "Hold" rating with limited upside potential.
Lantheus updates merger proxy: analysts value Lantheus stock at USD 98.00-129.00
Lantheus Holdings updated its merger disclosures on October 2, 2026, ahead of an October 14, 2026 stockholder vote, revealing analyst valuations of USD 98.00-129.00 per share and Morgan Stanley's analyses valuing the stock at USD 63.85-118.60 per share. The proposed transaction offers USD 102.50 per share in cash plus potential contingent value rights up to USD 12.00, totaling up to USD 114.50 per share. The company also reported Q2 2026 revenue of USD 388.18 million, a 2.70% year-over-year increase, with a market capitalization of USD 6.5 billion as of October 5, 2026.